Fig. 2From: Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective studyThe magnitude of numeric rating scale (NRS) improvement after 8 weeks of treatment with mirogabalin. No significant differences were observed in the magnitude of NRS improvement in patients taking maximum doses of 5 mg/day (n = 47), 10 mg/day (n = 89), 20 mg/day (n = 32), and 30 mg/day (n = 19). Data are expressed as the mean ± standard deviation. N.S., not significantBack to article page